FFO
CLDX icon

Fortitude Family Office’s Celldex Therapeutics CLDX Stock Holding History

Fortitude Family Office’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$595 Hold
16
– – ﹤0.01% 1936
2026
Q1 		$508 Buy
+16
New +$436 ﹤0.01% 1724
2025
Q3 		– Sell
-26
Closed -$529 – 2013
2025
Q2 		$529 Buy
+26
New +$506 ﹤0.01% 1780

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortitude Family Office's CLDX Position: Q2 2026 in Review

Fortitude Family Office held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 16 shares worth $595. The position accounts for ﹤0.01% of the portfolio, ranked #1936.

Fortitude Family Office first reported a position in CLDX in Q2 2025 and has held it in 3 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Fortitude Family Office held 16 shares of Celldex Therapeutics worth $595 as of Q2 2026.
  • Fortitude Family Office left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1936 holding.
  • Fortitude Family Office first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.